It’s the ‘closest thing to an HIV vaccine’, but who gets access?

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-30T22:20:45.344Z • Permanent link

Regeneron Pharmaceuticals' newest HIV treatment has sent shockwaves through the scientific community. The company's REGN-COV2, an antibody-based therapy, has been hailed as the "closest thing to an HIV vaccine" by some experts. REGN-COV2 is a two-antibody combination that targets different strains of the virus, and it has shown promising results in clinical trials.

Led by Dr. Rich Harrell, Regeneron's Chief Medical Officer, the team behind REGN-COV2 has been working tirelessly to develop a treatment that can combat the highly mutable nature of HIV. The company's efforts have been recognized with a $650 million grant from the National Institutes of Health (NIH) to support the development of REGN-COV2. The treatment has already been approved for emergency use in several countries, including the United States, South Africa, and Brazil.

However, despite the promising results, access to REGN-COV2 remains a significant issue. The treatment is not cheap, with a price tag of around $2,000 per patient per month. In the United States, the cost of the treatment is estimated to be around $10,000 per year. This makes it inaccessible to many low-income individuals, particularly in countries with limited healthcare resources.

The rollout of REGN-COV2 has significant implications for the pharmaceutical industry, particularly for companies that specialize in HIV treatments. Companies like Gilead Sciences, which has dominated the HIV market with its PrEP treatment, are likely to face increased competition from Regeneron. This could lead to a shift in market share and potentially drive down prices, making HIV treatments more accessible to a wider range of patients.

Furthermore, the development of REGN-COV2 highlights the need for greater investment in HIV research and treatment. The global HIV epidemic is one of the most significant public health crises of our time, and it is imperative that we prioritize access to effective treatments. Governments, non-profit organizations, and the private sector must work together to ensure that HIV treatments are accessible to all, regardless of income or geographic location.

The development of REGN-COV2 is part of a larger pattern of innovation in HIV treatment. In recent years, there has been a surge in investment in HIV research, driven by advances in technology and the growing recognition of the need for more effective treatments. Companies like Biogen and Pfizer have also developed new HIV treatments, including oral medications and combination therapies.